Clinical Trial Search

Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…

Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…

Primary: The Area of the Transperineal Targeted Microwave Ablation (TMA) Induced Tissue Death Assessed by Triphenyltetrazolium Chloride (TTC) Staining

Primary: All Cause Mortality — 171; 183 Participants

Primary: Sensitivity of PSMA-PET and MRI Imaging Preoperatively for Predicting Extra-prostatic Extension — 86; 57 percentage — p=<0.05

Primary: Combined pCR or MRD Rate [Part 1] — 12; 12 Participants

Primary: Total Milligrams of Opiates — 5.15; 2.52 mg — p=0.0012

Primary: Changes From Baseline to After Surgery of Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Infiltrates — 132.2; 153.7; 105.1; 140.5…

Primary: Number of Participants With Dose Limiting Toxicities (Phase I and Safety Run-In) — 0; 0 Participants

Primary: Apoptotic Index of the Highest Gleason Grade Malignant Epithelium in the Radical Prostatectomy Specimen Obtained After 8-weeks of the Dietary Intervention — 6.9; 5.0…

Primary: Proportion of Participants With Clinically Significant Psychological Distress (Kessler Psychological Distress Scale-10 ≥20) — 9; 14; 57; 48 Participants — p=0.031

Primary: Pathologic Complete Response Was Assessed by Rigorous Pathological Examination by One of Two Pathologists — 0 participants

Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g

Primary: Maximum Tolerated Dose (MTD) of Radiation Dose to Prostate Bed and Dose to Tumor Reported in Gray (Gy) — 36.4; 44.2; 47.1 Gray (Gy)

Primary: Change in International Prostate Symptom Scale (IPSS) of Lower Urinary Tract Symptoms From Baseline to 3 Months (Total Score at 3 Months Minus Total Score at Baseline)…

Primary: International Prostate Symptom Score (IPSS) Change — -17.5 units on a scale

Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151

Primary: Feasibility and Safety Using an Improved, More Efficient and Less Labor Intensive Cooling Balloon in Patients Undergoing Hypothermic Nerve-sparing RLP in Participants…

Primary: Number of Participants With 5-year Freedom From Prostate Specific Antigen (PSA) Recurrence. — 30 participants

Primary: Number of Participants Free From Progression at 3 Years — 54 participants

Primary: Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment — 45.5 percentage

Primary: Preservation of Ejaculation — 34; 8 Participants

Primary: Change in Penile Length — 0.3; 1.6 centimeters

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: To Evaluate the Efficacy of Bevacizumab Plus Erlotinib — 9; 1; 2; 7 participants

Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants

Primary: International Prostate Symptom Score (IPSS) — 6.8; 5.6 units on a scale

Primary: To Evaluate the Clinical Efficacy of Enzalutamide — 31 months

Primary: Pathologic Complete Response Rate — 8.7; 0.0; 4.3; 0.0 percentage of participants

Primary: Pathologic Complete Response at the Time of Surgery — 10; 8; 0 Participants